A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
A small single-centre randomised trial testing weight-lowering hypoglycaemic agents plus a high-protein diet and moderate exercise against standard care for diabetes remission in adults with obesity. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
A 149-patient inpatient randomized trial found an AI insulin titration system noninferior to senior physicians for time-in-range glucose control. PICO summary and expert commentary.
An acute randomised trial in 57 sedentary adults with type 2 diabetes found a single HIIT session raised flow-mediated dilation more than moderate continuous exercise, while both lowered post-exercise glucose. PICO summary and expert commentary.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.
A single-centre Korean pilot RCT of a physician-led digital education and remote-monitoring platform in type 2 diabetes, where both arms reached the same 3-month HbA1c and the early gain reversed once monitoring stopped. PICO summary and expert commentary.
A pooled analysis of three finerenone trials found a modest reduction in new-onset atrial fibrillation/flutter across the cardio-kidney-metabolic spectrum. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.